NCT01377870View on ClinicalTrials.gov

Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

April 30, 2014

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

intravenous injection of mesenchymal stem cells

15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell

BIOLOGICAL

injection of cell free media

Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.

Trial Locations (1)

Unknown

Royan Institute, Tehran

All Listed Sponsors
lead

Royan Institute

OTHER_GOV

NCT01377870 - Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis | Biotech Hunter | Biotech Hunter